USA Compression Partners, LP - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on August 3, 2020, by USA Compression Partners, LP. The filing details the execution of Amendment No. 1 to the Partnership's Sixth Amended and Restated Credit Agreement with JPMorgan Chase Bank, N.A., as agent.
Key Financial Metrics and Debt Obligations
- Outstanding Borrowings: Approximately $435.0 million as of the close of business on August 3, 2020.
- Letters of Credit: No outstanding letters of credit under the Credit Agreement.
- Maturity Date: The Credit Agreement matures in April 2023.
- Interest Margin Adjustment: The applicable margin for Eurodollar borrowings increased from a range of 2.00%-2.75% to 2.25%-3.00% during the Covenant Relief Period.
Material Changes and Covenant Modifications
The First Amendment introduces significant changes to financial covenants and payment restrictions effective August 3, 2020:
- Increased Debt-to-EBITDA Ratio: The maximum funded debt to EBITDA ratio was raised to 5.75:1.00 for the quarters ending September 30, 2020, and December 31, 2020. It steps down to 5.50:1.00 for the first half of 2021 and 5.25:1.00 for the second half of 2021, reverting to 5.00:1.00 thereafter.
- Acquisition Flexibility: The 0.5 increase in the debt ratio for acquisitions is deferred until the fiscal quarter ending September 30, 2021, with a cap of 5.50:1.00.
- Restricted Payment Thresholds: During the "Covenant Relief Period" (through December 31, 2021), the required availability to make restricted payments (from capital contributions or available cash) and to prepay senior notes or other indebtedness increased from $100 million to $250 million.
- Guaranty Expansion: The Partnership became a guarantor of the obligations of all other guarantors under the Credit Agreement.
Outlook, Risks, and Unusual Items
The filing does not provide specific forward-looking guidance, revenue projections, or management commentary regarding operational outlook. The primary focus is on securing covenant relief to manage liquidity and debt capacity during the specified period. The Partnership incurred amendment fees and arrangement fees in connection with this transaction.
Key Facts for Investor Verification
- Verify the impact of the increased interest margin (2.25%-3.00%) on future interest expense.
- Confirm the Partnership's ability to maintain the new, higher debt-to-EBITDA ratios given current EBITDA levels.
- Review the specific terms of the $250 million availability requirement for restricted payments and debt prepayments.
- Examine the full text of Exhibit 10.1 for complete details on the amendment terms not summarized in the 8-K.